Canada Pension Plan Investment Board Purchases Shares of 334,246 Alnylam Pharmaceuticals, Inc. $ALNY

Canada Pension Plan Investment Board acquired a new stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 334,246 shares of the biopharmaceutical company’s stock, valued at approximately $100,618,000.

A number of other institutional investors and hedge funds have also made changes to their positions in ALNY. Daiwa Securities Group Inc. raised its position in shares of Alnylam Pharmaceuticals by 0.3% in the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after buying an additional 35 shares during the period. Golden State Wealth Management LLC grew its position in Alnylam Pharmaceuticals by 100.0% during the fourth quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock valued at $29,000 after acquiring an additional 36 shares during the period. Coldstream Capital Management Inc. increased its stake in Alnylam Pharmaceuticals by 2.4% during the third quarter. Coldstream Capital Management Inc. now owns 1,640 shares of the biopharmaceutical company’s stock worth $748,000 after acquiring an additional 38 shares during the last quarter. Atlantic Union Bankshares Corp increased its stake in Alnylam Pharmaceuticals by 20.9% during the fourth quarter. Atlantic Union Bankshares Corp now owns 231 shares of the biopharmaceutical company’s stock worth $92,000 after acquiring an additional 40 shares during the last quarter. Finally, Laird Norton Wetherby Wealth Management LLC raised its holdings in shares of Alnylam Pharmaceuticals by 3.3% in the 3rd quarter. Laird Norton Wetherby Wealth Management LLC now owns 1,266 shares of the biopharmaceutical company’s stock worth $577,000 after purchasing an additional 40 shares during the period. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, Director David E. I. Pyott sold 3,830 shares of the business’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the transaction, the director directly owned 1,582 shares of the company’s stock, valued at approximately $473,302.76. The trade was a 70.77% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals Trading Down 0.4%

Shares of ALNY opened at $239.00 on Thursday. The stock’s 50-day moving average is $264.27 and its two-hundred day moving average is $294.77. The stock has a market cap of $31.98 billion, a PE ratio of 44.42 and a beta of 0.30. Alnylam Pharmaceuticals, Inc. has a 12 month low of $197.81 and a 12 month high of $495.55. The company has a debt-to-equity ratio of 0.75, a current ratio of 3.05 and a quick ratio of 2.99.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, July 30th. The biopharmaceutical company reported $1.84 earnings per share for the quarter, topping the consensus estimate of $1.63 by $0.21. Alnylam Pharmaceuticals had a return on equity of 84.93% and a net margin of 15.26%.The company had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.32 billion. During the same quarter in the prior year, the business earned ($0.51) earnings per share. The company’s revenue was up 66.9% compared to the same quarter last year. Equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post 6.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the company. Truist Financial reduced their price objective on Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating on the stock in a research note on Tuesday, August 4th. Needham & Company LLC dropped their target price on shares of Alnylam Pharmaceuticals from $510.00 to $357.00 and set a “buy” rating for the company in a research report on Thursday, July 30th. Wall Street Zen lowered shares of Alnylam Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 2nd. HC Wainwright reduced their price target on shares of Alnylam Pharmaceuticals from $485.00 to $455.00 and set a “buy” rating on the stock in a research report on Friday, July 31st. Finally, Citigroup decreased their price objective on shares of Alnylam Pharmaceuticals from $380.00 to $340.00 and set a “buy” rating for the company in a research note on Monday, August 3rd. Three investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and five have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $386.14.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.